Regina Graul, Ph.D., Takes Charge as Cyclerion's New CEO

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) has announced the elevation of Regina Graul, Ph.D., to the positions of Chief Executive Officer, President, and Board Member. Dr. Graul, who took on the role of President in December 2023, has made significant contributions to enhancing the company’s operations.

Collaborating closely with the Board of Directors, she is focused on maximizing shareholder value by streamlining Cyclerion’s operational expenses. In addition, she is spearheading a top-tier search and evaluation team that is currently assessing various business development opportunities that align with Cyclerion’s strengths.

Errol DeSouza, Ph.D., Chairperson of Cyclerion Therapeutics, said in a statement, “From the day Regina arrived at Cyclerion, she has done impressive work, quickly assessing the state of the company, challenging the status quo and executing on strategic objectives. She has been the momentum, driving the assessment of new therapies for patients, and looking for ways to enhance value for shareholders. What Cyclerion has accomplished under her leadership in this short time is notable, and we have great confidence in her ability to steer Cyclerion to a new era of growth and success.”

Dr. Graul said, “I am enthusiastic about stepping into the CEO role and continuing to shepherd the evolution of Cyclerion. In partnership with the finance team, we have reduced operational costs while forming a top-notch diligence team – comprised of external experts in their respective fields – currently in advanced stages of conducting promising asset evaluations.

Graul further added, With multiple exciting possibilities to choose from, we look forward to building a vibrant new future for Cyclerion. I have a clear view of the amount of work and risks that we are facing, but I believe we have the know-how and grit to build upon Cyclerion’s current foundation to achieve new heights and unlock value for both patients and shareholders.”

Dr. Graul boasts over 20 years of experience in the biopharmaceutical sector, establishing herself as a driving force for advancement in various roles. As a leader focused on growth, she emphasizes innovation and fosters a creative work environment. Before becoming President in December 2023, Regina served as Vice President at EQRx, where she simultaneously led multiple large cross-functional development teams in the oncology space.

Her prior roles include heading internal innovation, acting as a strategic program leader, and collaborating with business development to uncover licensing opportunities at Cyclerion. Dr. Graul began her career as a medicinal chemist at Ironwood Pharmaceuticals (formerly Microbia Inc.) after completing her postdoctoral research at MIT, where she contributed to the development of molecules that advanced to clinical trials. She earned her Ph.D. in synthetic organic chemistry from Rice University and holds a B.A. in chemistry from Saint Anselm College.